Kris M. White

This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.

This paper identifies a small molecule, M4, that inhibits influenza A and B replication by targeting the host protein STARD7, preventing vRNP nuclear export and demonstrating synergistic antiviral effects with baloxavir in mice.

The paper compares three data analysis methods for MERS-CoV MPro inhibitors, finding that modeling the complete concentration-response curve best predicts cellular efficacy.

The paper investigates structure-activity relationships of pleconaril analogues against EV-D68, identifying compounds with antiviral activity and favorable ADME properties.

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

The paper identifies potent nsp3-mac1 inhibitors but finds they do not translate to antiviral activity in cell culture models.

The paper systematically analyzes proteomic and genomic data of SARS-CoV-2 variants to identify how mutations affect viral gene expression, host interactions, and immune evasion.

The paper generates bat induced pluripotent stem cells and finds they contain endogenous viral sequences, suggesting a deep entanglement between bats and viruses.

A computational drug repositioning pipeline identifies potential therapeutics for COVID-19 by matching SARS-CoV-2 gene expression signatures to drug profiles.

Affinity-purification mass spectrometry of 26 SARS-CoV-2 proteins in HEK293T cells yields 332 high-confidence host interactions and 67 druggable human proteins with known compounds.